Skip to main content
. Author manuscript; available in PMC: 2023 Jun 1.
Published in final edited form as: Contraception. 2023 Feb 12;122:109975. doi: 10.1016/j.contraception.2023.109975

Figure 3.

Figure 3.

Plasma levonorgestrel concentration versus time profile over 48 weeks post-implant insertion for women with HIV receiving double-dose levonorgestrel implants (300 mg) plus efavirenz-based antiretroviral therapy (n=27, solid line) compared with women without HIV taking standard-dose levonorgestrel implant (150 mg) alone (n=19, dashed line) [12]. Data presented as medians and interquartile ranges.